Technology evaluation results of the injection preparation kit and System | |
---|---|
File download : 성균관대 BT 강소기업 상생지원센터_기술가치평가서(메인텍).pdf | |
Anti-cancer (injection) preparation
automation device selected as a BIG3 project by applying for a patent in May
2020 and The injection-integrated cylinder pump technology was awarded the
highest value before product sales as a result of the ACPi patent technology
evaluation by the Technology Credit Guarantee Fund (Technology New Report) with
the project budget (about KRW 20 million) of the BIG3 project support
organization. (Please, find the attached file) With patented technology, the highest
evaluation amount in the technology new report before sales does not exceed 500
million won and in general, an evaluation of 300 million won is common. The result of valuation of 500 million won
as a patented technology that has been commercialized and did not generate
sales proves that ACPi is the best technology. With manual ACPi and CAM which the concept
design was completed, the production was completed this month with, Yesterday's
Korea University and today's National Cancer Center were mostly satisfied with
the results of market research with 3D animation videos. The CAM that the company will develop is
when a pharmacist who prepares an anticancer drug puts the anticancer drug
bottle on the cup holder and operates the switch and the MCSTD (CSTD developed
by the company) is automatically connected to the anticancer drug bottle and
converted into an extraction mode. When extracting anticancer drugs with a
syringe, it is not easy to extract the entire amount as high as the height of
the injection needle, so we will solve the difficulty to extract the entire
amount. CAM is a technology that ACPi V100 extracts
the entire amount without leakage because the MCSTD and the anticancer bottle
are closely contacted during the preparation process. It is expected to be well received by
pharmaceutical pharmacists, which solves a large part of the ease of
preparation and the risk of exposure to cancer drugs. The weight is also less
than 5Kg and it is compact, so it seems that CAM alone will have considerable
meaning. As a result of marketization that meets the
highest technology value evaluation before product sales, we will do our best
to achieve the patented technology value of several trillion won that the
company targets. Thank you for the hard work of Sungkyunkwan
University Dr. Kang Soo-Jung and all of the people involved in doing their best
for the evaluation. Thank you. |
Next | Video clip for patented technology MCST, manual ACPi V100 including CAM |
---|---|
Prev | MFDS (KFDA) approval of Anyfusion blood transfusion pump (BTP) and Development of CAM |